- Home
- TSHA vs MRVI Comparison
TSHA vs MRVI Comparison
Compare TSHA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- MRVI
- Stock Information
- Founded
- TSHA 2019
- MRVI 2014
- Country
- TSHA United States
- MRVI United States
- Employees
- TSHA N/A
- MRVI N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- MRVI Health Care
- Exchange
- TSHA Nasdaq
- MRVI Nasdaq
- Market Cap
- TSHA 356.7M
- MRVI 347.5M
- IPO Year
- TSHA 2020
- MRVI 2020
- Fundamental
- Price
- TSHA $1.38
- MRVI $2.21
- Analyst Decision
- TSHA Strong Buy
- MRVI Hold
- Analyst Count
- TSHA 8
- MRVI 10
- Target Price
- TSHA $6.63
- MRVI $7.59
- AVG Volume (30 Days)
- TSHA 1.6M
- MRVI 3.9M
- Earning Date
- TSHA 05-13-2025
- MRVI 03-18-2025
- Dividend Yield
- TSHA N/A
- MRVI N/A
- EPS Growth
- TSHA N/A
- MRVI N/A
- EPS
- TSHA N/A
- MRVI N/A
- Revenue
- TSHA $8,333,000.00
- MRVI $259,185,000.00
- Revenue This Year
- TSHA N/A
- MRVI $3.80
- Revenue Next Year
- TSHA N/A
- MRVI $11.15
- P/E Ratio
- TSHA N/A
- MRVI N/A
- Revenue Growth
- TSHA N/A
- MRVI N/A
- 52 Week Low
- TSHA $1.17
- MRVI $2.07
- 52 Week High
- TSHA $4.32
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- TSHA 34.93
- MRVI 29.01
- Support Level
- TSHA $1.59
- MRVI $2.07
- Resistance Level
- TSHA $1.87
- MRVI $2.43
- Average True Range (ATR)
- TSHA 0.15
- MRVI 0.19
- MACD
- TSHA -0.01
- MRVI 0.05
- Stochastic Oscillator
- TSHA 24.36
- MRVI 21.88
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.